TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31284074
Drug: Low-dose colchicine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose colchicine (0.5 mg daily)
Study: 27613939
Drug: 4mg nicotine
Normalized name: nicotine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg nicotine lozenge
Study: 27613939
Drug: 4mg lozenge
Normalized name: MENTHOL 5.4MG LOZENGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg lozenge
Study: 26003545
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume strategy (4 to 6 ml/kg PBW)
Study: 26003545
Drug: High tidal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tidal volume strategy (8 to 10 ml/kg PBW)
Study: 23174860
Drug: α(1)-blockade (prazosin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: α(1)-blockade (prazosin, 1 mg/20 kg body wt)
Study: 21636583
Drug: PI‐free combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI‐free combination including efavirenz
Study: 21636583
Drug: PI‐free combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI‐free combination including nevirapine
Study: 21636583
Drug: PI‐free combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI‐free combination including abacavir
Study: 24843530
Drug: Pregabalin 150-600
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150-600 mg/day
Study: 19490035
Drug: Pregabalin 600
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 600 mg/day fixed-dosage
Study: 18997444
Drug: epalrestat (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: epalrestat (150 mg/day)
Study: 9261853
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone (10 mg/kg/day for 10 days)
Study: 8300814
Drug: FSH‐HP preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH‐HP preparation (sp. act. approximately 9000 IU FSH/mg of protein), administered as a single dose of 150 IU by i.v. injection to females and by i.m. and s.c. routes to males.
Study: 8300814
Drug: Standard urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard urinary FSH preparation (Metrodin), administered as a single dose of 150 IU by i.v. injection to females and by i.m. and s.c. routes to males.
Study: 3446307
Drug: Half-dose flupenthixol
Normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose flupenthixol decanoate
Study: 3446307
Drug: Standard-dose flupenthixol
Normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose flupenthixol decanoate
Study: 18845806
Drug: High-dose allopurinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose allopurinol (300 mg once a day)
Study: 18845806
Drug: Low-dose allopurinol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose allopurinol (100 mg once a day)
Study: 16339220
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg/day for 2 weeks
Study: 15093845
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac tromethamine
Study: 10569560
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg avorelin subcutaneous depot
Study: 10569560
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg avorelin subcutaneous depot
Study: 8758317
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (75 mg daily, n = 40)
Study: 6753112
Drug: Pirenzepine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 0.1 mg.kg-1
Study: 6753112
Drug: Pirenzepine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 0.25 mg.kg-1
Study: 6753112
Drug: Pirenzepine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 0.5 mg.kg-1
Study: 6753112
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg.kg-1)
Study: 6753112
Drug: Pirenzepine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (various doses)
Study: 24800828
Drug: Bivalent killed
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bivalent killed whole-cell oral cholera vaccine
Study: 11907287
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (for patients with dispatch to drug administration ≤ 24 minutes)
Study: 11907287
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (for patients with dispatch to drug administration ≤ 24 minutes)
Study: 2746444
Drug: Chlorhexidine spray,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine spray, applied twice a day
Study: 2746444
Drug: Chlorhexidine mouthwash,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine mouthwash, rinsed twice a day
Study: 27686946
Drug: Temozolomide chemotherapy
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide chemotherapy (75 mg/m2 once daily for 21 days, repeated every 28 days for a maximum of 12 cycles)
Study: 27686946
Drug: Radiotherapy (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (up to 50.4 Gy; 28 doses of 1.8 Gy once daily, 5 days per week for up to 6.5 weeks)
Study: 27686943
Drug: Temozolomide chemotherapy
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide chemotherapy
Study: 20696729
Drug: Early transition
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early transition group (transferred from incubator to open crib at >1600 g)
Study: 20696729
Drug: Standard transition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard transition group (transferred from incubator to open crib at >1800 g)
Study: 16313106
Drug: Jiangni Hewei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiangni Hewei Decoction (JHD), one dose per day for 8 weeks
Study: 16313106
Drug: Omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20 mg once per day for 8 weeks
Study: 12893712
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium concentration (680 mg/l)
Study: 12893712
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium concentration (410 mg/l)
Study: 9457940
Drug: T (50‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: T (50‐100 mg IM weekly) + desogestrel (150‐300 microg daily)
Study: 9457940
Drug: T (50‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: T (50‐100 mg IM weekly) + levonorgestrel (125‐250 microg daily)
Study: 27113442
Drug: telephone-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: telephone-delivered cognitive behavioural therapy (tCBT)
Study: 15713598
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m² on days 1, 8, and 15 of each 28-day cycle (3w4)
Study: 15713598
Drug: Gemcitabine 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,500 mg/m² on days 1 and 8 of each 21-day cycle (2w3)
Study: 12094857
Drug: Balsalazide (6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide (6.75 g daily)
Study: 22906581
Drug: Hotz plate
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hotz plate treatment
Study: 22906581
Drug: No Hotz
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Hotz plate treatment
Study: 17324249
Drug: R667 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: R667 0.2 mg
Study: 17324249
Drug: R667 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: R667 0.5 mg
Study: 17324249
Drug: R667 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: R667 1 mg
Study: 15606516
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with narrow filter (580-650 nm) at fluence rate of 30 mW cm(‐2)
Study: 15606516
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with narrow filter (580-650 nm) at fluence rate of 45 mW cm(‐2)
Study: 15606516
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with broad filter (580-690 nm) at fluence rate of 50 mW cm(‐2)
Study: 15606516
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with broad filter (580-690 nm) at fluence rate of 75 mW cm(‐2)
Study: 15606516
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with cumulative light dose of 40 J cm(‐2)
Study: 15606516
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with varying fluence rates from 30 to 75 mW cm(‐2)
Study: 15606516
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with cumulative light dose of 20 J cm(‐2)
Study: 11688021
Drug: Intra Mobiele
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra Mobiele Zylinder implants (IMZ group, n = 41)
Study: 11688021
Drug: Brånemark implants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brånemark implants (Brå group, n = 17)
Study: 11688021
Drug: Transmandibular Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmandibular Implant (TMI group, n = 29)
Study: 11688021
Drug: IMZ and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMZ and Brånemark implants
Study: 393027
Drug: Enterobiotic (antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enterobiotic (antibiotic prophylaxis)
Study: 28295766
Drug: Veterinarian-administered otic
Normalized name: Absorbine Veterinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veterinarian-administered otic gel (Group A)
Study: 28295766
Drug: Owner-administered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Owner-administered treatment (Group B)
Study: 25467586
Drug: AF-219, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: AF-219, 600 mg twice a day
Study: 20615594
Drug: Hi-TENS combined
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hi-TENS combined with PCA-morphine
Study: 20615594
Drug: PCA-morphine alone
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA-morphine alone
Study: 11560127
Drug: ACTH-[1-24] (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH-[1-24] (250 mg in 500 mL normal saline, infused at a constant rate over 8 h)
Study: 7843475
Drug: 12 plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 plasma glucose and insulin determinations
Study: 7843475
Drug: 26 plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26 plasma glucose and insulin determinations
Study: 2662897
Drug: Interferon and
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon and descyclovir therapy
Study: 31201041
Drug: High-Flow Nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Flow Nasal Oxygen (HFNO) at 50 L/min
Study: 31201041
Drug: Standard Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Oxygen Therapy (SOT) via a standard facemask
Study: 21266003
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus morphine sulfate
Study: 19139846
Drug: Cruciate retaining
Normalized name: Gentiana cruciata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cruciate retaining implants
Study: 9253908
Drug: Standard fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fat emulsion dose (L)
Study: 9253908
Drug: Withholding fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding fat infusions (NL)
Study: 8490316
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg for induction)
Study: 8490316
Drug: Thiopental (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (4 mg/kg for induction)
Study: 8490316
Drug: Propofol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1 mg/kg after intubation)
Study: 8490316
Drug: Thiopental (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (2 mg/kg after intubation)
Study: 27185372
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg fulvestrant
Study: 24091594
Drug: Intravenous ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibandronate (3 mg quarterly)
Study: 24091594
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate (70 mg weekly)
Study: 24852042
Drug: Ustekinumab 45
Normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 45 or 90 mg
Study: 8879436
Drug: Oestradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol (2 mg/day) alone
Study: 8879436
Drug: Oestradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol (2 mg/day) with norethisterone (1 mg/day)
Study: 8879436
Drug: Oestradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol (2 mg/day) alone (sub-set of 32 patients)
Study: 8879436
Drug: Oestradiol/norethisterone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol/norethisterone (1 mg/day)
Study: 6723349
Drug: Controlled-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release formulation of ketoprofen (2 capsules of 100 mg once daily)
Study: 6723349
Drug: Conventional capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional capsule formulation of ketoprofen (100 mg capsules twice daily)
Study: 30409490
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with weekly paclitaxel
Study: 30377220
Drug: Support for
Normalized name: GNP Diabetic Support Formula Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Support for free nicotine replacement therapy.
Study: 17346807
Drug: Regular desloratadine
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular desloratadine treatment
Study: 17346807
Drug: On-demand desloratadine
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-demand desloratadine treatment
Study: 12972521
Drug: EC plus
Normalized name: Ivomec Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC plus G-CSF (C group)
Study: 12972521
Drug: EC plus
Normalized name: Ivomec Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC plus LND plus G-CSF (D group)
Study: 8674092
Drug: Propafenone 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 600 mg
Study: 11789362
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control Group A)
Study: 6628707
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg dl-norgestrel and 0.1 mg ethinylestradiol administered orally at 18 hours after LH rise and again at 30 hours
Study: 24091849
Drug: Cisplatin +
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin + Paclitaxel (TP) 45 mg/m²/week
Study: 24091849
Drug: Cisplatin +
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin + Docetaxel (DP) 20 mg/m²/week
Study: 24091849
Drug: Cisplatin +
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin + Gemcitabine (GP) 350 mg/m²/week
Study: 21840467
Drug: AquADEKs chewable
Normalized name: AquADEKs Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: AquADEKs chewable tablets
Study: 21840467
Drug: AquADEKs capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: AquADEKs capsules
Study: 21840467
Drug: Vitamins A
Normalized name: Vitamins A & D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins A (3 mg daily), E (200 mg daily), and D(3) (20 μg daily)
Study: 15097304
Drug: Enrollment in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrollment in the preventive HIV vaccine trial
Study: 15097304
Drug: Concerns about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concerns about vaccine-induced seropositivity
Study: 8489107
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 500 mg/kg weekly
Study: 3829912
Drug: Ranitidine HCl
Normalized name: ranitidine HCl
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine HCl 150 mg
Study: 3829912
Drug: Cimetidine HCl
Normalized name: cimetidine HCl
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine HCl 400 mg
Study: 1572123
Drug: Oral tetrahydroaminoacridine
Normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetrahydroaminoacridine (THA) and lecithin (75 to 200mg per day)
Study: 2865021
Drug: Somatostatin intravenous
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin intravenous infusion
Study: 30449234
Drug: AR101 (peanut-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR101 (peanut-derived investigational biologic oral immunotherapy)
Study: 28372591
Drug: Cooperation between
Normalized name: COOPER (AS CUPRIC OXIDE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooperation between geriatricians and general practitioners involving clinical geriatric assessment, medication review, and clinical follow-up over 24 weeks.
Study: 26106623
Drug: Insulin sensitizing
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin sensitizing medications (thiazolidinediones and metformin)
Study: 26106623
Drug: Insulin provision
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin provision strategy (insulin and/or sulfonylureas)
Study: 20878571
Drug: FOLFOX chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX chemotherapy (Group A, n=22)
Study: 6316120
Drug: Levamisole as
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole as an adjunct to chemotherapy and radiotherapy
Study: 6316120
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as an adjunct to chemotherapy and radiotherapy
Study: 29660046
Drug: Optometrists providing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optometrists providing advice on smoking cessation medications
Study: 27013060
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg bid (with or without 180 mg loading dose)
Study: 27013060
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg bid (with loading dose)
Study: 27013060
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg bid (without loading dose)
Study: 27013060
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg QD
Study: 19643320
Drug: Atorvastatin reload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin reload (80 mg 12 h before intervention, with a further 40-mg pre-procedural dose)
Study: 11313190
Drug: Electric toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electric toothbrush (Oral‐B‐7 EB 5 K, Braun AG, Kronberg, Germany)
Study: 11313190
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush (Oral‐B, Power Tip, Braun AG, Kronberg, Germany)
Study: 21246854
Drug: Auricular point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular point sticking (group A) - semen vaccariae fixed with plaster on various ear points, pressed 3 times daily for 5 mm each time, alternating sides every two days.
Study: 21246854
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of auricular point sticking and body acupuncture (group B) - same ear points as group A, plus body acupuncture at specific points (Zhongwan, Juanyuan, Tiansho, Zusanli, Sanyinjiao), applied once every two days.
Study: 10214748
Drug: Rapid titration
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid titration of pramipexole (full converted dose the day after stopping the former agonist)
Study: 10214748
Drug: Slow titration
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow titration of pramipexole (up to 8 weeks to reach equivalent dosage)
Study: 19352247
Drug: Particulate injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Particulate injections (5 bone marrow aspirates and cyst injections)
Study: 19352247
Drug: Steroid injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injections (2 injections)
Study: 18381307
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow injection
Study: 15162891
Drug: SFGC 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFGC 62.5 mg administered over 30 minutes
Study: 15162891
Drug: SFGC 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFGC 125 mg administered over 60 minutes
Study: 15162891
Drug: SFGC 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFGC 62.5 mg administered over 4 minutes (second dose)
Study: 15162891
Drug: SFGC 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFGC 125 mg administered over 7 minutes (second dose)